Cross-Over Evaluation of Two Lubricating Eye Drops

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00493662
Recruitment Status : Completed
First Posted : June 28, 2007
Last Update Posted : January 15, 2008
Information provided by:
Innovative Medical

Brief Summary:
To evaluate the efficacy of two lubricating eye drops for the treatment of dry eye signs and symptoms.

Condition or disease Intervention/treatment Phase
Dry Eye Drug: Polyethylene Glycol 400 0.4% Drug: Propylene Glycol 0.3% Drug: 0.15% sodium Hyaluronate Drug: sodium chloride Drug: sodium phosphate monobasic Phase 4

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Care
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Patients 18 yrs or older
  2. Males or females
  3. Any race or ethnic background
  4. Patients with present ocular surface discomfort and a SESoD score of at least 2

Exclusion Criteria:

  1. Corneal refractive surgery within 6 months of this study.
  2. Contact lens use on day of examination.
  3. Corneal ectasia.
  4. Current use of Restasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00493662

United States, Pennsylvania
Hazleton Eye Specialists
Hazleton, Pennsylvania, United States, 18202
Sponsors and Collaborators
Innovative Medical
Principal Investigator: Tom Kislan, OD Hazleton Eye Specialists Identifier: NCT00493662     History of Changes
Other Study ID Numbers: 5310
First Posted: June 28, 2007    Key Record Dates
Last Update Posted: January 15, 2008
Last Verified: January 2008

Additional relevant MeSH terms:
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents